The FDA has designated Stoboclo and Osenvelt as interchangeable biosimilars to the reference products Prolia and Xgeva, respectively.

The new approvals bring the number of denosumab biosimilars in the US to eight, but price reductions are not yet substantial.

The U.S. Food and Drug Administration (FDA) has approved two new biosimilars as reference products for Prolia (denosumab) and XGEVA® (denosumab): Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo ...

The FDA has designated Conexxence and Bomyntra as interchangeable biosimilars to the reference products Prolia and Xgeva, ...

Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced today that the U.S. Food and Drug Administration (FDA ...

Prolia® is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily ...

Older women who received denosumab (Prolia, Amgen) for up to 10 years for osteoporosis had a low risk of osteonecrosis of the jaw (ONJ), although the risk was higher — albeit still quite small — if ...

A study comparing denosumab (Prolia) with risedronate (Actone) found that denosumab could be a useful treatment option for patients newly initiating or continuing glucocorticoids who are at risk of ...

GlycoNex, Inc. (4168, hereinafter referred to as GNX), today announced that the last patient has received the final dose in ...

Please provide your email address to receive an email when new articles are posted on . Adults with osteoporosis who received more than one dose of denosumab had a reduced risk for developing diabetes ...

Among 1,032 Japanese patients on dialysis who started treatment for osteoporosis, denosumab use had a 45% lower risk for a composite of all fractures compared with oral bisphosphonates over 3 years ...

A post hoc analysis of five randomized controlled trials suggests that older adults with osteoporosis assigned denosumab therapy were 20% less likely to experience a fall during follow-up compared ...